Tandem Diabetes Care Stock Performance
| TNDM Stock | USD 20.29 0.36 1.74% |
The entity has a beta of 1.12, which indicates a somewhat significant risk relative to the market. Tandem Diabetes returns are very sensitive to returns on the market. As the market goes up or down, Tandem Diabetes is expected to follow. At this point, Tandem Diabetes Care has a negative expected return of -0.83%. Please make sure to validate Tandem Diabetes' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Tandem Diabetes Care performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Tandem Diabetes Care has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (1.74) | Five Day Return 1.4 | Year To Date Return (43.39) | Ten Year Return (84.28) | All Time Return (89.47) |
Last Split Factor 1:10 | Dividend Date 2017-10-10 | Last Split Date 2017-10-10 |
1 | Disposition of 595 shares by Rick Carpenter of Tandem Diabetes subject to Rule 16b-3 | 02/18/2025 |
2 | Tandem Investment Advisors Inc. Buys 67 Shares of McDonalds Co. | 02/21/2025 |
3 | Tandem Diabetes Care Inc Reports Strong Financial Growth in 2024 | 02/26/2025 |
4 | Heres What Key Metrics Tell Us About Tandem Diabetes Care Q4 Earnings | 02/27/2025 |
5 | Bernstein downgrades Tandem Diabetes on market share loss concerns | 03/03/2025 |
6 | Advisor360 Introduces Tandem A CRM for Independent Financial Advisors | 03/04/2025 |
7 | Tandem Diabetes stock downgraded at Morgan Stanley | 03/05/2025 |
8 | North Mill poised to acquire Pawnee Leasing, Tandem Finance | 03/06/2025 |
9 | Reasons to Hold TNDM Stock in Your Portfolio for Now | 03/11/2025 |
10 | Disposition of 406 shares by Rick Carpenter of Tandem Diabetes subject to Rule 16b-3 | 03/17/2025 |
11 | Tandem Diabetes Care Launches New Control-IQ Automated Insulin Delivery Technology in the United States | 03/18/2025 |
12 | Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ AID Technology in Type 2 Diabetes | 03/19/2025 |
13 | Tandem Diabetes Care Inc Announces Positive Results from Control-IQ Trial for Type 2 ... | 03/21/2025 |
14 | Acquisition by Susan Morrison of 1504 shares of Tandem Diabetes subject to Rule 16b-3 | 03/24/2025 |
| Begin Period Cash Flow | 58.9 M |
Tandem |
Tandem Diabetes Relative Risk vs. Return Landscape
If you would invest 3,700 in Tandem Diabetes Care on December 24, 2024 and sell it today you would lose (1,671) from holding Tandem Diabetes Care or give up 45.16% of portfolio value over 90 days. Tandem Diabetes Care is currently does not generate positive expected returns and assumes 5.2384% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Tandem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tandem Diabetes Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tandem Diabetes' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tandem Diabetes Care, and traders can use it to determine the average amount a Tandem Diabetes' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1583
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TNDM |
Estimated Market Risk
| 5.24 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.83 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tandem Diabetes is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tandem Diabetes by adding Tandem Diabetes to a well-diversified portfolio.
Tandem Diabetes Fundamentals Growth
Tandem Stock prices reflect investors' perceptions of the future prospects and financial health of Tandem Diabetes, and Tandem Diabetes fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tandem Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0645 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 1.38 B | ||||
| Shares Outstanding | 66.47 M | ||||
| Price To Earning | 494.25 X | ||||
| Price To Book | 5.13 X | ||||
| Price To Sales | 1.43 X | ||||
| Revenue | 940.2 M | ||||
| Gross Profit | 489.57 M | ||||
| EBITDA | (99.13 M) | ||||
| Net Income | (96.03 M) | ||||
| Cash And Equivalents | 608.73 M | ||||
| Cash Per Share | 9.47 X | ||||
| Total Debt | 473.56 M | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 4.80 X | ||||
| Book Value Per Share | 3.97 X | ||||
| Cash Flow From Operations | 24.23 M | ||||
| Earnings Per Share | (1.47) X | ||||
| Market Capitalization | 1.35 B | ||||
| Total Asset | 967.66 M | ||||
| Retained Earnings | (1.05 B) | ||||
| Working Capital | 477.44 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 26.52 M | ||||
About Tandem Diabetes Performance
By examining Tandem Diabetes' fundamental ratios, stakeholders can obtain critical insights into Tandem Diabetes' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Tandem Diabetes is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 121.18 | 173.07 | |
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.36) | (0.35) |
Things to note about Tandem Diabetes Care performance evaluation
Checking the ongoing alerts about Tandem Diabetes for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tandem Diabetes Care help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tandem Diabetes Care generated a negative expected return over the last 90 days | |
| Tandem Diabetes Care has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 940.2 M. Net Loss for the year was (96.03 M) with profit before overhead, payroll, taxes, and interest of 489.57 M. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Tandem Diabetes Care Inc Announces Positive Results from Control-IQ Trial for Type 2 ... |
- Analyzing Tandem Diabetes' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tandem Diabetes' stock is overvalued or undervalued compared to its peers.
- Examining Tandem Diabetes' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tandem Diabetes' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tandem Diabetes' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tandem Diabetes' stock. These opinions can provide insight into Tandem Diabetes' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 0.436 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.